Lundbeck Limited Company Profile

17:18 EST 18th December 2018 | BioPortfolio

As a pharmaceutical manufacturer, Lundbeck is unique in that we focus solely on the treatment of diseases of the central nervous system. Our aim is to be the world leader in the development of pharmaceuticals for psychiatric and neurological disorders, and are pioneers of new treatments and new approaches.
As specialists, our research and development is focused and concentrated. As specialists, we maintain close ties to our customers, establishing new links, building knowledge and developing new programmes. And as specialists, we are closer to the people suffering from psychiatric disorders and the people treating them.


Lundbeck HouseCaldecotte Lake Drive
Caldecotte Lake
Milton Keynes
United Kingdom


Phone: 44 1908 649966
Fax: 44 1908 647888

News Articles [97 Associated News Articles listed on BioPortfolio]

Lundbeck brings third Parkinson's drug into clinic

Denmark’s Lundbeck is bringing a third potential drug for Parkinson’s disease to the clinic – a human antibody that the company hopes will tackle the underlying cause of the condition. The comp...

Otsuka and Lundbeck report positive brexpiprazole results

Otsuka Pharmaceutical and Lundbeck have reported positive results from three Phase III studies evaluating the safety and efficacy of brexpiprazole...Read More... The post Otsuka and Lundbeck report po...

Lundbeck and Otsuka Announce Positive Phase 2 Data for Combination Treatment of Brexpiprazole and Sertraline in Post-Traumatic Stress Disorder

Valby, Denmark and Tokyo, Japan, 30 November 2018 – H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced today the achievement of positive clinical results (in inte...

Deborah Dunsire Takes Over as CEO of Denmark’s H. Lundbeck

Former XTuit Pharmaceuticals Chief Executive Officer Deborah Dunsire has been appointed head of Denmark-based H. Lundbeck A/S.

Lundbeck craters as resistant schizophrenia drug fails phase III

Danish drugmaker Lundbeck saw more than a quarter of the value wiped off its shares yesterday after its top pipeline prospect, a drug for schizophrenia, missed the mark in a phase III trial. In the 1...

The Darkest Hour Is After DAYBREAK For Lundbeck’s New Antipsychotic

The first Phase III study for Lundbeck’s novel antipsychotic flops leaving the Danish company shares down by 25% as investors...   

Generic Blow Looms For Lundbeck

With a new CEO taking the reins in September and a candidate entering the clinic for Parkinson’s disease, Lundbeck has...   

VIDEO: Lundbeck Still Assessing Future Of Antipsychotic After Phase III Failure, Says CEO

Deborah Dunsire, Lundbeck’s new CEO, talks to Scrip about the fallout from its recent Phase III setback, and how she...   

Drugs and Medications [59 Associated Drugs and Medications listed on BioPortfolio]



Drug Facts


Famotidine Tablets, USP 20 mg

Neoprofen [Lundbeck Inc.]

These highlights do not include all the information needed to use NeoProfen safely and effectively. See full prescribing information for NeoProfen. NeoProfen (ibuprofen lysine) Injection for intraveno...

Facility maintenance instant hand sanitizer hs-67 [Knight Facilities Management, Inc.]

Facility Maintenance Instant Hand Sanitizer HS-67

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Multiple-therapy-resistant major depressive disorder: a clinically important concept.

SummaryMany novel therapeutic options for depression exist that are either not mentioned in clinical guidelines or recommended only for use in highly specialist services. The challenge faced by clinic...

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease

The purpose of this study is to investigate the utility of dopamine transporter imaging in monitoring and predicting the progression of Parkinson disease. This study will be performed in ...

Companies [102 Associated Companies listed on BioPortfolio]

Lundbeck LLC

Lundbeck in the U.S., headquartered in Deerfield, Illinois, is a wholly-owned subsidiary of H. Lundbeck A/S in Denmark. Lundbeck is committed to accelerating advances in brain dis...

Lundbeck Inc.

Lundbeck Inc. was established in March 2009 following the acquisition of Ovation Pharmaceuticals, Inc. by Lundbeck and has proven success in developing and commercializing high-ne...


Depression, schizophrenia, Alzheimer's, Parkinson's, epilepsy, Multiple Sclerosis, and migraines have their foundation in the Central Nervous System - our key focus areas. Lundbeck's entire R&D effort...


The Lundbeck Institute is pleased to present Psychotropics Online, a comprehensive guide to CNS compounds and products.We have published Psychotropics since the 1960s in a printed handbook version, an...

Lundbeck Limited

As a pharmaceutical manufacturer, Lundbeck is unique in that we focus solely on the treatment of diseases of the central nervous system. Our aim is to be the world leader in the development of pharmac...

More Information about "Lundbeck Limited" on BioPortfolio

We have published hundreds of Lundbeck Limited news stories on BioPortfolio along with dozens of Lundbeck Limited Clinical Trials and PubMed Articles about Lundbeck Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Lundbeck Limited Companies in our database. You can also find out about relevant Lundbeck Limited Drugs and Medications on this site too.

Quick Search


Relevant Topic

Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...

Corporate Database Quicklinks

Searches Linking to this Company Record